Talimogene Laherparepvec

Talimogene Laherparepvec (Lmlygic®), which received FDA approval on 27 October 2015, is used in patients whose disease cannot be surgically removed, with melanoma, as the first cancer vaccine treatment acting through direct injection into the melanoma area. Talimogene laherparepvec administration is a treatment method using genetically modified viruses. In this way, it can regulate cancer cell division and proliferation and enable the immune system to work more effectively.

Its best-known side effects are fatigue, chills, high fever and nausea.